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The tripeptide glutathione (GSH) is instrumental to antioxidant protection and xenobiotic metabolism, and the
ratio of its reduced and oxidized forms (GSH/GSSG) indicates the cellular redox environment and maintains key
aspects of cellular signaling. Disruptions in GSH levels and GSH/GSSG have long been tied to various chronic
diseases, and many studies have examined whether variant alleles in genes responsible for GSH synthesis and
metabolism are associated with increased disease risk. However, past studies have been limited to established,
canonical GSH genes, though emerging evidence suggests that novel loci and genes influence the GSH redox
system in specific tissues. The present study marks the most comprehensive effort to date to directly identify
genetic loci associated with the GSH redox system. We employed the Diversity Outbred (DO) mouse population, a
model of human genetics, and measured GSH and the essential redox cofactor NADPH in liver, the organ with the
highest levels of GSH in the body. Under normal physiological conditions, we observed substantial variation in
hepatic GSH and NADPH levels and their redox balances, and discovered a novel, significant quantitative trait
locus (QTL) on murine chromosome 16 underlying GSH/GSSG; bioinformatics analyses revealed Socs1 to be the
most likely candidate gene. We also discovered novel QTL associated with hepatic NADP+ levels and NADP+/
NADPH, as well as unique candidate genes behind each trait. Overall, these findings transform our understanding
of the GSH redox system, revealing genetic loci that govern it and proposing new candidate genes to investigate
in future mechanistic endeavors.

1. Introduction
Glutathione is a ubiquitous and versatile intracellular antioxidant
[1]. A tripeptide comprised of glycine, glutamate, and cysteine, its
biochemical functions are mediated by a sulfhydryl group on the
cysteine residue [2]. In the cell, glutathione mostly exists in its reduced
thiol form (GSH), and enzymes such as glutathione peroxidase (GPx) and
glutaredoxins convert it to the dimer glutathione disulfide (GSSG),
which is recycled back to two molecules of GSH via NADPH-dependent
glutathione reductase (GR) [1,3]. Though GSH and GSSG are in a con
stant state of flux, their levels – and the ratio GSH/GSSG, or 2GSH/GSSG
– provide an informative glimpse into the redox environment of the cell
and shifts in these values often indicate oxidative stress [1,4]. Further
more, decreases in tissue GSH levels and GSH/GSSG, and corresponding
increases in GSSG levels, have been observed in a wide array of chronic
diseases including liver disease [5,6], chronic kidney disease [7,8], heart
disease [9,10], diabetes mellitus [11–13], and obesity [14].

Because of the close relationship between GSH and chronic diseases,
many studies have sought to determine whether variant alleles in genes
encoding GSH-related enzymes, including GPx and GR, predict chronic
disease risk in human populations. GPX1 polymorphisms have been
associated with increased risk of breast cancer [15,16], chronic kidney
disease [17], prostate cancer [18], coronary artery disease [19], acute
myeloid leukemia [19], and diabetes-related kidney complications [20].
Moreover, variants in GPX isoforms have been associated with risk for
arterial ischemic stroke in young adults and children (GPX3) [21] and
prepubertal childhood obesity (GPX4, 5, and 6) [22], though these
trends have not been consistent across all populations [23–28]. Other
studies have examined the disease relevance of polymorphisms in genes
involved in glutathione biosynthesis, notably glutathione cysteine ligase
(GCL) and glutathione synthetase (GS), which directly affect cellular
GSH concentrations [29]. Polymorphisms in the catalytic subunit of GCL
(GCLC) have been associated with cystic fibrosis [30], chronic
obstructive pulmonary disease [31], pulmonary tuberculosis [32], drug
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promptly blotted on a paper towel, and flash frozen in liquid nitrogen.
Within 12 h of each harvest, samples were homogenized in PBS con
taining 10 mM diethylenetriaminepentaacetic acid (DTPA) and
promptly acidified with an equal volume of ice-cold 10% perchloric acid
(PCA) containing 1 mM DTPA as previously described [52,61]. Acidified
samples underwent centrifugation (15,000 RPM at 4C for 15 min) and
the acidified supernatant was collected and filtered. Filtered supernatant
samples were stored at − 80◦ C until analysis, and all samples were
analyzed within 6 months. GSH and GSSG concentrations were quanti
fied in each sample by HPLC coupled with electrochemical detection
(Dionex Ultimate 3000, Thermo Fisher Scientific, Waltham, MA USA)
based on previously published methods [61]. A conditioning cell was set
to +500 mV and placed immediately before the boron-doped diamond
cell which was set at +1475 mV with a cleaning potential at +1900 mV
between samples. The mobile phase consisted of 4.0% acetonitrile, 0.1%
pentafluoropropionic acid, and 0.02% ammonium hydroxide. The flow
rate was maintained at 0.22 mL/min and injection volumes were set at
5.0 μL. Peaks were quantified using external GSH and GSSG standards,
external calibration, and the Chromeleon Chromatography Data System
Software (Dionex Version 7.2, Thermo Fisher Scientific, Waltham, MA
USA). Total glutathione concentrations were determined by calculating
[GSH] + [2GSSG] and all glutathione concentrations were standardized
to total protein (Pierce BCA Protein Assay, Thermo Fisher Scientific,
Waltham, MA USA) and expressed in nmol/mg protein. The ratio of
GSH/GSSG was then calculated. Another commonly reported measure
ment related to GSH dynamics and oxidative stress is the redox potential
Eh of the redox couple [62–67]. To calculate the redox potential (Eh) of
the GSSG-GSH pair (2GSH →GSSG +2e− +2H+ ) in each liver sample, we
used the Nernst equation at 40 ◦ C:

sensitivity in human tumor cell lines [33], methylmercury retention
[34], vasomotor function and myocardial infarction [35,36]. Functional
polymorphisms in the GCL modifier subunit (GCLM) have been linked
with ischemic heart disease and vasomotor function [36,37], and in
some cases, schizophrenia [38–40]. Lastly, polymorphisms in GS have
been associated with susceptibility to lung dysfunction and lung cancer,
as well as patient survival [41,42]. Mutations in these genes have also
been found in patients with inborn errors in glutathione metabolism,
though the diseases are rare [43–47].
While most genetics studies have focused on core genes with estab
lished functions in GSH biosynthesis and metabolism, emerging evi
dence suggests that novel loci and genes impact tissue GSH dynamics as
well. Multiple studies have shown that GSH and GSSG levels and GSH/
GSSG are heritable in mice [48–52] and humans [53] alike, and Zhou
et al. discovered new genetic loci associated with hepatic GSH levels and
GSH/GSSG in mice [51]. However, those genes were found using a panel
of inbred mouse strains, which do not fully reflect the human condition,
and many in silico mapping tools have limited power and a predisposi
tion toward false positives [54–56]. Thus, more powerful and compre
hensive approaches are needed to identify genes that truly govern tissue
GSH levels and redox balance, and ultimately, affect chronic disease
risk.
In the present study, we performed genome-wide analysis of hepatic
GSH and GSSG levels, as well as GSH/GSSG, in the Diversity Outbred
(DO) mouse stock, which models the genetic diversity of humans and
facilitates high-precision mapping of quantitative trait loci (QTL) [57,
58]. To best understand the genetics of the entire GSH system [59], we
expanded our analysis to include the redox cofactor NADPH, which is
essential for GSH recycling [60], and its precursor NADH. To our
knowledge, this is the most comprehensive genetic mapping study to
focus on tissue GSH homeostasis, and overall, our results point to novel
loci and candidate genes that will vastly expand our understanding of
this essential redox system and its regulation.

Eh = E0 +

RT [ (ox) ]
ln
nF (red)

Eh = measured cell potential, E0 = standard electrode potential for
GSSG/2GSH (− 264 mV at pH 7.4 [63–65]), R = gas constant (8.3145 J x
mol− 1 x K− 1), T = temperature in Kelvin (313.15 K), n = number of
electrons transferred (2), F = Faraday’s constant (96485C x mol− 1), ox
= molar concentration of oxidant (GSSG), and red = molar concentra
tion of reductant (GSH). The exponential of GSH reflects the stoichi
ometry where 2 GSH are oxidized per 1 GSSG formed [62]. Tissue
concentrations of GSH and GSSG (nmol/mg protein) were expressed in
molar concentrations [66,67] using a conversion factor of 500 μL/mg of
protein. The final equation used to calculate Eh (mV) for the GSSG-GSH
couple was:
]
[
(GSSG)
Eh (mV) = − 264 + 31 log
(GSH)2

2. Materials and methods
2.1. Mice
Male and female Diversity Outbred (DO) mice (J:DO; JAX®
#009376) from generations 30, 32, and 35 were purchased from The
Jackson Laboratory (Bar Harbor, ME USA); the DO stock was originally
generated from eight inbred founder strains: A/J (AJ), C57BL/6J (B6),
129S1/SvImJ (129), NOD/ShiLtJ (NOD), NZO/HlLtJ (NZO), CAST/EiJ
(CAST), PWK/PhJ (PWK), and WSB/EiJ (WSB). All mice arrived at 4
weeks of age and were given ad libitum access to water and standard
chow diet (LabDiet®, St. Louis, MO USA, product 5053) and kept on a 12
h light-dark cycle. These conditions were maintained until the mice
were sacrificed at 5–6 months of age. Prior to sacrifice, and during the
light cycle, all mice were fasted for 3–4 h. Then mice were humanely
euthanized by cervical dislocation and tissues were collected for anal
ysis. A total of 351 mice (174 males, 177 females) were sacrificed, and at
the time of harvest, total body weight (g), liver weight (g), and liver
weight/body weight (%) were documented (Supplementary
Tables S1–S3; Supplementary Figure S1). The University of Georgia
Institutional Animal Care and Use Committee (IACUC) approved all
methods and procedures involving animals in accordance with the
ethical standards of the institution (AUP #A2016-07-016), and all
methods and procedures were carried out in accordance with the Na
tional Institutes of Health guide for the care and use of Laboratory an
imals (NIH Publications No. 8023, revised 1978).

2.3. Assessment of hepatic NADPH, NADP+, NADP+/NADPH, and
NADH
Liver samples collected at harvest were rinsed with ice-cold PBS,
blotted on a paper towel, and flash frozen in liquid nitrogen. Within 12 h
of each harvest, samples were homogenized, processed, and analyzed by
kit (NADP/NADPH Quantification Kit and NAD/NADH Quantification
Kit, MilliporeSigma, Burlington, MA USA) according to the manufac
turer’s instructions. All nicotinamide adenine dinucleotide (NAD) phe
notypes were standardized to total protein (Pierce BCA Protein Assay,
Thermo Fisher Scientific, Waltham, MA USA) and expressed in pmol/μg
protein.
2.4. Genotyping

2.2. Assessment of hepatic total glutathione, GSH, GSSG, and redox
ratios

Genotyping was performed on all 351 DO samples. DNA was
extracted from tail tips collected at sacrifice and subsequently geno
typed using the third-generation Mouse Universal Genotyping Array
(GigaMUGA) [68] performed by GeneSeek (Neogen Genomics, Lincoln,

Samples of liver tissue were promptly harvested from each mouse
after humane euthanasia. Tissues were rinsed with ice-cold PBS,
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Table 1
Descriptive statistics for hepatic redox system metabolites in DO mice.
Phenotype

N

x‾

Median

SD

Min

Max

Total Glutathione (nmol/mg)
GSH (nmol/mg)
GSSG (nmol/mg)
GSH/GSSG
Eh (mV)
NADPH (pmol/μg)
NADP+ (pmol/μg)
NADP+/NADPH
NADH (pmol/μg)

346
346
347
346
346
335
331
319
332

45.945
44.695
0.627
78.052
− 195.278
0.262
0.981
9.888
2.788

43.045
41.971
0.558
74.714
− 195.477
0.238
0.890
3.694
2.788

19.215
18.708
0.346
25.120
7.707
0.170
0.450
19.499
1.233

10.183
9.843
0.140
31.894
− 215.556
0.011
0.157
0.460
0.293

117.232
113.359
2.288
177.181
− 166.948
0.898
2.575
161.363
7.572

NE USA, 68504). This 143K-probe array is built on the Illumina Infinium
II platform and has been optimized for genetic mapping in the DO
populations.

R/qtl2 find_peaks and bayes_int functions [58,71]. To estimate allelic
contributions of the eight founder strains at specific QTL, we used the
Best Linear Unbiased Predictors (BLUPs) model within R/qtl2 [73].
Genes within Bayesian credible intervals ±1 Mbp were plotted using
R/qtl2 via connection with the Mouse Genome Informatics (MGI)
database. All genotype data, genotype probabilities, and marker infor
mation are publicly available through figshare (https://doi.org/10.
6084/m9.figshare.c.5360501.v1). All source code, phenotype data,
and other files used in QTL analyses are available through a public
GitHub repository (https://doi.org/10.5281/zenodo.4683881).

2.5. Quantitative trait loci (QTL) mapping
Genome scans were performed using 347 (172 male, 175 female) of
the original 351 DO samples; 2 mice were excluded from QTL analysis
because they were XO females, and 2 were excluded due to low call
rates. Prior to analysis, all phenotypic data underwent z-score trans
formation to ensure normality [69]. We then performed genomes scans
using R/qtl2 software [58], and for each phenotype, scans included sex
and experimental cohort as additive covariates. Each genome scan
model also accounted for kinship among the DO mice using the “leave
one chromosome out” (LOCO) method [58,70]. Significance thresholds
were determined for individual traits by performing 1000 permutations
[58,71,72], and we applied a suggestive threshold (p-value≤0.20) for
reporting QTL loci based on the permutation analysis [72]. A 95%
Bayesian credible interval was calculated around each peak using the

2.6. Candidate gene analysis
To interrogate the plausibility of candidate genes within significant
and suggestive loci, we used an integrative bioinformatics approach that
queried databases for expression, phenotypic, and functional annota
tions based on previously published methods [74,75]. First, we identi
fied all protein-coding and functional RNA genes within the significant
QTL intervals ±1 Mbp reported by R/qtl2 using the Unified Mouse

Fig. 1. Variation in hepatic glutathione concentrations and redox balance in the DO population. Hepatic concentrations of A. Total Glutathione (GSH+2GSSG,
expressed in nmol/mg); B. GSH (nmol/mg); C. GSSG (nmol/mg); D. GSH/GSSG; and E. Redox Potential of the GSSG-GSH couple, indicated as Eh (mV) were
measured in a population of DO mice. Values are arranged from smallest to largest, and the N for each measurement is provided underneath each panel.
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Fig. 2. Variation in hepatic NAD(P)H concentrations and redox balances in the DO population. Hepatic concentrations of A. NADPH (pmol/μg); B. NADP+ (pmol/
μg); C. NADP+/NADPH; and D. NADH (pmol/μg) in a population of DO mice. Values are arranged from smallest to largest, and the N for each measurement is
provided underneath each panel.

Genome Feature Catalog within the Mouse Genome Informatics (MGI)
database. Second, for each genome feature in the region, we compiled
expression annotations from the bioinformatics resources listed in
Supplementary Table S4. Gene expression annotations were collected
from the EBI Expression Atlas (EEA) [76] and the Gene eXpression
Database (GXD) [77] through MGI [78]. Functional annotations were
collected using InterPro [79] and Gene Ontology (GO) annotations [80,
81] obtained through MGI [78]. All phenotypic data relevant to the liver
were collected from PheWeb [82] and Ensembl BioMart [83].

NADPH and its precursor NADH (Table 1; Fig. 2). NADP+ concentrations
ranged from 0.157 to 2.575 pmol/μg, over a 16-fold difference, while its
reduced form NADPH ranged from 0.011 to 0.898 pmol/μg, over an 81fold difference. NADP+/NADPH ranged from 0.460 to 161.363, over a
350-fold difference. NADH ranged from 0.293 to 7.572 pmol/μg, over a
25-fold difference. Sex-specific values are found in Supplementary
Tables S5 and S6.
We screened for statistical associations among variables and
discovered multiple significant correlations. Association results are lis
ted in Table 2 and shown visually in Fig. 3. Hepatic total glutathione
concentrations were positively correlated with GSH concentrations (ρ =
1.000, p = <0.001), GSSG concentrations (ρ = 0.801, p = <0.001), and
GSH/GSSG levels (ρ = 0.120, p = 0.026), and were strongly negatively
correlated with Eh levels (ρ = − 0.799, p = <0.001). Hepatic GSH con
centrations were positively correlated with GSSG concentrations (ρ =
0.791, p = <0.001) and GSH/GSSG levels (ρ = 0.137, p = 0.011), and
were negatively correlated with Eh levels (ρ = − 0.810, p = <0.001).
Hepatic GSSG concentrations were negatively correlated with GSH/
GSSG levels (ρ = − 0.443, p = <0.001) and Eh levels (ρ = − 0.326, p =
<0.001). Hepatic GSH/GSSG levels were negatively correlated with Eh
levels (ρ = − 0.652, p = <0.001).
Hepatic NADPH concentrations were positively correlated with total
glutathione concentrations (ρ = 0.265, p = <0.001), GSH concentra
tions (ρ = 0.267, p = <0.001), and GSSG concentrations (ρ = 0.203, p =
<0.001), and negatively correlated with NADP+ concentrations (ρ =
− 0.278, p = <0.001), NADP+/NADPH levels (ρ = − 0.846, p = <0.001)
and Eh levels (ρ = − 0.234, p = <0.001). Hepatic NADP+ concentrations
were negatively correlated with total glutathione concentrations (ρ =
− 0.306, p = <0.001), GSH concentrations (ρ = − 0.306, p = <0.001),
GSSG concentrations (ρ = − 0.269, p = <0.001), and NADP+ concen
trations (ρ = − 0.142, p = 0.010), and positively correlated with NADP+/
NADPH levels (ρ = 0.711, p = <0.001) and Eh levels (ρ = 0.226, p =
<0.001). Hepatic NADP+/NADPH levels were positively correlated with
Eh levels (ρ = 0.240, p = <0.001) and negatively correlated with total
glutathione concentrations (ρ = − 0.296, p = <0.001), GSH concentra
tions (ρ = − 0.297, p = <0.001), and GSSG concentrations (ρ = − 0.233,
p = <0.001). Neither NADPH or NADP+, nor the NADP+/NADPH ratio
were found to be correlated with GSH/GSSG (p = 119, p = 0.850, and p
= 0.208, respectively). Hepatic NADH concentrations were positively
correlated with NADPH (ρ = 0.191, p = 0.001), total glutathione

2.7. Statistical analysis
IBM SPSS Statistics version 26 (SPSS Inc., Chicago, IL USA) was used
to detect the significance of relationships between variables of interest.
Mann-Whitney tests were used to compare variables between sex to
elucidate any sex-effects between variables, and the test included a U
statistic and a standard error. RStudio version 1.3.1093 (RStudio, PBC.,
Boston, MA USA) and R version 4.0.2 (R Foundation for Statistical
Computing, Vienna, Austria) were used to evaluate correlations between
values and rank-based Spearman’s rho (ρ) was calculated for each
relationship. A relationship between variables was considered statisti
cally significant if the p-value was less than 0.05.
3. Results
3.1. Hepatic GSH and NADPH vary significantly among outbred mice
In a large cohort of genetically-diverse DO mice, we measured he
patic concentrations of GSH and GSSG, as well as GSH/GSSG, and found
that under normal physiological conditions, these phenotypes vary
widely (Table 1; Fig. 1). Hepatic concentrations of total glutathione and
GSH exhibited an over 11-fold difference, ranging from 10.183 to
117.232 nmol/mg and 9.843 to 113.359 nmol/mg, respectively. Hepatic
GSSG concentrations ranged from 0.140 to 2.288 nmol/mg, reflecting a
16-fold difference, and GSH/GSSG ranged from 31.894 to 177.181, over
a 5-fold difference. We observed a significant degree of variation in
hepatic Eh with a range of − 215.556 to − 166.948 mV, a 1.3-fold dif
ference. There were no sex effects observed for any of these phenotypes
(Supplementary Tables S5 and S6).
A similar degree of variation was observed in the redox cofactor
4
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calculated through 1000 permutation tests. Genome-wide scans for he
patic concentrations of total glutathione and GSH revealed a suggestive
peak (LOD scores 6.755 and 6.748, respectively) on mouse chromosome
14 (founder allele effects and candidate gene results are included in
Supplementary Figures S2 and S3). Mapping GSH/GSSG and Eh revealed
a significant (p-value ≤ 0.05) peak on mouse chromosome 16 at 8.998
Mbp (LOD scores 8.224 and 8.598, respectively). Given that the peak
position was the same between the two scans, we focused on GSH/GSSG
results, which are outlined in Fig. 5, while Eh results are provided in
Supplementary Figure S4.
The genome-wide scan for GSH/GSSG revealed a significant peak on
mouse chromosome 16 with a QTL interval of 8.865–10.077 Mbp
(Fig. 5A). Within the interval, founder allele effects were extrapolated,
showing that the AJ allele contributes to a higher GSH/GSSG, whereas
the 129 allele contributes to a lower GSH/GSSG (Fig. 5B). Genes found
within this interval ±1 Mbp were plotted using R/qtl2 through
connection with the MGI database (Fig. 5C), and functional RNA and
protein-coding genes were collected and screened for physiological
relevance using existing expression, functional, and phenotypic anno
tations (Supplementary Table S7). The QTL interval contained 66
possible candidate genes: 29 protein-coding, 35 non-coding RNA, and 2
unclassified (GRCm38/mm10; gene query performed November 2020,
Feature Type “gene” [78]). 30 of the 66 GSH/GSSG candidate genes had
limited hepatic expression annotations and were therefore excluded. Of
the remaining 36 candidate genes, 22 were limited to hepatic expression
data only, and the remaining 14 candidate genes had annotations with
functional relevance to the GSH redox system: transmembrane protein
114 (Tmem114), predicted gene 5767 (Gm5767), RIKEN cDNA
1810013L24 gene (1810013L24Rik), ribosomal protein L39-like
(Rpl39l), activating transcription factor 7 interacting protein 2
(Atf7ip2), predicted gene 1600 (Gm1600), nucleotide binding protein 1
(Nubp1), trans-golgi network vesicle protein 23A (Tvp23a), class II
transactivator (Ciita), C-type lectin domain family 16, member A
(Clec16a), suppressor of cytokine signaling-1 (Socs1), protamine 3
(Prm3), protamine 2 (Prm2), and LPS-induced TN factor (Litaf). Based on
functional
and
phenotypic
annotations,
Socs1
(Chr16:10783808–10785536 bp; 5.81 cM; GRCm38) was determined to
be the most likely candidate gene within the interval. SOCS1 functions
as a negative regulator of cytokine signaling, including the
JAK/STAT-signaling pathway, as well as insulin and toll-like receptor
(TLR) signal transduction [84]. Importantly, SOCS1 has been involved
in p53 activation and subsequent repression of the transcription of
SLC7A11 [85] – a cystine/glutamate antiporter and regulator of intra
cellular cysteine concentrations, the rate-limiting precursor for GSH
biosynthesis [86,87]. As a result of its suppression of SLC7A11, SOCS1
expression has been found to negatively correlate with GSH levels [85].
Furthermore, SOCS1 negatively regulates the nuclear factor-κB (NF-κB)
transcription complex, specifically the p65 subunit, by acting as a
ubiquitin ligase and prompting proteasome-mediated degradation [88].
NF-κB is transcription factor and activation of NF-κB is critical in
maintaining cellular GSH concentrations [89] and expression of en
zymes involved in GSH synthesis [90].

Table 2
Statistical relationships among markers of the hepatic GSH redox system as well
as liver weights.
Spearman’s rho (ρ) was calculated for each variable combination. Total gluta
thione, GSH, and GSSG concentrations were standardized as nmol/mg protein.
Concentrations of NADPH, NADP, and NADH were standardized as pmol/μg
protein. Eh was expressed as mV. Liver weight was reported in grams (g). * in
dicates a significant relationship (p≤0.05).
Variables

ρ

p-value

Total Glutathione, GSH
Total Glutathione, GSSG
Total Glutathione, GSH/GSSG
Total Glutathione, Eh
Total Glutathione, NADPH
Total Glutathione, NADP+
Total Glutathione, NADP+/NADPH
Total Glutathione, NADH
GSH, GSSG
GSH, GSH/GSSG
GSH, Eh
GSH, NADPH
GSH, NADP+
GSH, NADP+/NADPH
GSH, NADH
GSSG, GSH/GSSG
GSSG, Eh
GSSG, NADPH
GSSG, NADP+
GSSG, NADP+/NADPH
GSSG, NADH
GSH/GSSG, Eh
Eh, NADPH
Eh, NADP+
Eh, NADP+/NADPH
Eh, NADH
NADPH, NADP+
NADPH, NADP+/NADPH
NADPH, NADH
NADP+, NADP+/NADPH
NADP+, NADH
NADP+/NADPH, NADH
Liver Weight, Total Glutathione
Liver Weight, GSH
Liver Weight, GSSG
Liver Weight, GSH/GSSG
Liver Weight, Eh
Liver Weight, NADPH
Liver Weight, NADP+
Liver Weight, NADP+/NADPH
Liver Weight, NADH

1.000*
0.801*
0.120*
− 0.799*
0.265*
− 0.306*
− 0.296*
0.250*
0.791*
0.137*
− 0.810*
0.267*
− 0.306*
− 0.297*
0.253*
− 0.443*
− 0.326*
0.203*
− 0.269*
− 0.233*
0.123*
− 0.652*
− 0.234*
0.226*
0.240*
− 0.307*
− 0.278*
− 0.846*
0.191*
0.711*
− 0.142*
− 0.181*
0.137*
0.136*
0.176*
− 0.089
− 0.050
0.203*
− 0.218*
− 0.262*
− 0.063

<0.001
<0.001
0.026
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.011
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.025
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.001
<0.001
0.010
0.001
0.011
0.012
0.001
0.099
0.349
<0.001
<0.001
<0.001
0.253

concentrations (ρ = 0.250, p = <0.001), GSH concentrations (ρ = 0.253,
p = <0.001), GSSG concentrations (ρ = 0.123, p = 0.025), GSH/GSSG
levels (ρ = 0.186, p = 0.001), and were negatively correlated with
NADP+/NADPH levels (ρ = − 0.181, p = 0.001), and Eh levels (ρ =
− 0.307, p = <0.001).
Relationships between redox phenotypes and liver weights were also
observed, with positive associations between liver weights and total
glutathione concentrations (ρ = 0.137, p = 0.011), GSH concentrations
(ρ = 0.136, p = 0.012), and GSSG concentrations (ρ = 0.176, p = 0.001).
Liver weights were also positively correlated with NADPH concentra
tions (ρ = 0.203, p = <0.001) and negatively correlated with NADP+
concentrations (ρ = − 0.218, p = <0.001) and NADP+/NADPH (ρ =
− 0.262, p = <0.001). NADH was not correlated with liver weight (ρ =
− 0.063, p = 0.253).

3.3. QTL mapping of the hepatic NAD(P)H phenotypes
Genome-wide scans were conducted for the following NADPH redox
phenotypes: NADPH, NADP+, NADP+/NADPH, and NADH (Fig. 6).
Scans for NADPH and NADH included peaks that surpassed LOD score 6
or more yet failed to reach significance. The genome-wide scan for
NADP+ revealed a suggestive peak (p-value≤0.20) on mouse chromo
some 3 at 110.517 Mbp (LOD score 7.032) with a QTL interval of
109.677–115.729 Mbp (Fig. 7A). Founder allele effects showed that the
WSB and PWK alleles contribute to a higher NADP+ concentration,
whereas the NOD and CAST alleles contribute to a lower NADP+ con
centration (Fig. 7B). Genes located within this interval ±1 Mbp were
plotted using R/qtl2 (Fig. 7C) and existing biological annotations were

3.2. QTL mapping of the hepatic GSH redox system
We performed QTL analysis using R/qtl2 on all measured markers of
the GSH redox system (Fig. 4). Here we outline the results of statistically
significant peaks, yet it should be noted that multiple other peaks sur
passed LOD scores of 6 but failed to surpass significance thresholds
5
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Fig. 3. Correlation matrix of statistical relation
ships among markers of the hepatic GSH redox
system and liver weights. Spearman’s rho (ρ) was
calculated for each variable combination and is
listed within each corresponding box. Total gluta
thione, GSH, and GSSG concentrations were stan
dardized as nmol/mg protein. Concentrations of
NADPH, NADP, and NADH were standardized as
pmol/μg protein. Eh was expressed as mV. Liver
weight was reported in grams (g). A colored box
indicates a significant relationship (p≤0.05). An
uncolored (white) box indicates an insignificant
relationship (p>0.05).

Fig. 4. QTL results for markers of the GSH redox system. Genome-wide scans of hepatic A. Total Glutathione (GSH+2GSSG, expressed in nmol/mg); B. GSH (nmol/
mg); C. GSSG (nmol/mg); D. GSH/GSSG; and E. Redox Potential of the GSSG-GSH couple (Eh, expressed as mV). Permutation-derived significance thresholds are
indicated by colored lines at significance (α) levels 0.05 (blue), 0.1 (red), and 0.2 (purple). (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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Fig. 5. High-resolution association mapping for hepatic GSH/GSSG in outbred mice reveals a significant QTL on mouse chromosome 16. A. Genome-wide scan of
hepatic GSH/GSSG in outbred mice shows a QTL with peak LOD score 8.224 at 8.998 Mbp (4.779 cM) on mouse chromosome 16. Permutation-derived significance
thresholds are indicated by colored lines at significance (α) levels 0.05 (blue), 0.1 (red), and 0.2 (purple). B. The founder allele QTL effects indicate that the 129 allele
contributes to a lower hepatic GSH/GSSG concentration, whereas the AJ allele contributes to a higher hepatic GSH/GSSG concentration. Each colored line represents
a DO founder allele as indicated in the legend. The differences between strains are considered significant when the LOD score (bottom) crosses significance thresholds
(panel A). C. Candidate genes found within the QTL interval relative to the MGI database. Eh (mV) genome scan resulted in the same significant QTL interval on
mouse chromosome 16 compared to GSH/GSSG (Supplementary Figure S4). (For interpretation of the references to color in this figure legend, the reader is referred
to the Web version of this article.)

collected. The QTL interval contained 85 possible candidate genes: 38
protein-coding, 37 non-coding RNA, and 10 unclassified (Supplemen
tary Table S8; GRCm38/mm10; gene query performed November 2020,
Feature Type “gene” [78]). 52 of the 85 NADP+ candidate genes had no
hepatic expression and were therefore excluded. Of the remaining 33
candidate genes, 8 had no additional functional or phenotypic annota
tions related to hepatic redox function. The remaining 25 candidate
genes were: chloride channel CLIC-like 1 (Clcc1), G-protein signaling
modulator 2 (Gpsm2), AKNA domain containing 1 (Aknad1), syntaxin
binding protein 3 (Stxbp3), PRP38 pre-mRNA processing factor 38
(yeast) domain containing B (Prpf38b), HEN1 methyltransferase homo
log 1 (Henmt1), family with sequence similarity 102, member B
(Fam102b), solute carrier family 25, member 54 (Slc25a54), vav 3
oncogene (Vav3), netrin G1 (Ntng1), protein arginine N-methyl
transferase 6 (Prmt6), RNA-binding region containing 3 (Rnpc3), olfac
tomedin 3 (Olfm3), RIKEN cDNA A930005H10 gene (A930005H10Rik),
diphthamide biosynthesis 5 (Dph5), solute carrier family 30 (zinc

transporter), member 7 (Slc30a7), exostoses-like 2 (Extl2), vascular cell
adhesion molecule 1 (Vcam1), CDC14 cell division cycle 14A (Cdc14a),
RNA 3′ -terminal phosphate cyclase (Rtca), dihydrolipoamide branched
chain transacylase E2 (Dbt), leucine rich repeat containing 39 (Lrrc39),
tRNA methyltransferase 13 (Trmt13), SAS-6 centriolar assembly protein
(Sass6), and solute carrier family 35 (UDP-N-acetylglucosamine
(UDP-GlcNAc) transporter), member 3 (Slc35a3). Evaluation of func
tional and phenotypic annotations did not point to a single candidate
with a direct link to NADP+ regulation. Yet a subsequent literature
search suggested that Vav3, Vcam1, and Cdc14a were the most likely
concentrations.
Vav3
genes
influencing
NADP+
(Chr3:109340653–109685698 bp; 48.13 cM; GRCm38) is a Rho GTPase
regulating guanine nucleotide exchange factor (GEF) [91]. The Vav
protein family, including Vav3, are key activators of the Card9/NF-κB
pathway in immunity [92]. VCAM-1 (Chr3: 116110020–116129688 bp;
50.17 cM; GRCm38) expression is upregulated by NF-κB and increases in
oxidative stress [93,94], and VCAM-1 activates NADPH oxidase in
7
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Fig. 6. QTL results for hepatic NAD(P)H phenotypes. Genome-wide scans of hepatic A. NADPH (pmol/μg); B. NADP+ (pmol/μg); C. NADP+/NADPH; and D. NADH
(pmol/μg). Permutation-derived significance thresholds are indicated by colored lines at significance (α) levels 0.05 (blue), 0.1 (red), and 0.2 (purple). (For
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

endothelial cells [95]. CDC14A (Chr3: 116272553–116428741bp;
50.24 cM; GRCm38) is a phosphoprotein-phosphatase involved in cell
cycle progression [96]. CDC14A has been found to dephosphorylate
tumor suppressor p53 and is thought to regulate the function of p53 [97,
98] whose actions are critical in regulating NADPH redox status and
NADPH production through the pentose phosphate pathway [99,100].
We were unable to find research supporting the involvement of Vav3,
Vcam-1, or Cdc14a’s involvement with hepatic NF-κB or p53, nor their
influence on hepatic NADP+.
The genome-wide scan for NADP+/NADPH revealed a suggestive
peak (p-value≤0.10) on mouse chromosome 12 at 28.626 Mbp (LOD
score 7.637) with a QTL interval of 28.562–29.394 Mbp (Fig. 8A).
Founder allele effects were extrapolated within the interval and show
that the WSB and B6 alleles contribute to a higher NADP+/NADPH ratio,
whereas the NOD and PWK alleles contribute to a lower NADP+/NADPH
ratio (Fig. 8B). Genes found within this credible interval ±1 Mbp were
plotted using R/qtl2 through connection with the MGI database
(Fig. 8C) for collection of functional RNA and protein coding genes. The
QTL interval contained 51 possible candidate genes: 15 protein-coding,
34 non-coding RNA, and 2 unclassified (GRCm38/mm10; gene query
performed November 2020, Feature Type “gene” [78]). Biological an
notations were collected (Supplementary Table S9), and 36 of the 51
NADP+/NADPH candidate genes had no hepatic expression annotations
and were therefore excluded. 6 of the remaining 15 candidate genes did
not have additional functional or phenotypic annotations related to
hepatic redox function, and the remaining 9 candidate genes were: SRY
(sex determining region Y)-box 11 (Sox11), collecting sub-family
member 11 (Colec11), ribosomal protein S7 (Rps7), ribonuclease H1
(Rnaseh1), acireductone dioxygenase 1 (Adi1), myelin transcription
factor 1-like (Myt1l), peroxidasin (Pxdn), thyroid peroxidase (Tpo), and
syntrophin, gamma 2 (Sntg2). A comprehensive literature search on each
gene failed to suggest evidence of their influence on hepatic

NADP+/NADPH levels or redox homeostasis.
4. Discussion
GSH is a core regulator of the cellular redox environment and its
biochemistry has been thoroughly investigated since its discovery in the
late 19th century [101]. Yet in recent years, studies have suggested that
GSH is also controlled at a genetic level [48–53], though the specific loci
and genes have remained unidentified. Here, we utilized the DO popu
lation, a model of human genetics, to map loci underlying indicators of
the hepatic GSH redox system, including the essential cofactor NADPH
and its precursor NADH. Through these efforts, we discovered novel loci
and candidate genes responsible for hepatic GSH/GSSG, as well as
NADP+ and NADP+/NADPH, shifting existing paradigms surrounding
the role of genetics in redox regulation.
In this study, genome-wide association mapping revealed a novel
locus for GSH/GSSG on murine chromosome 16 at 8.998 Mbp (p≤0.05),
a region that contains 66 candidate genes. Via bioinformatic database
query, we identified Socs1 as the most plausible candidate gene for
multiple reasons. First, Socs1 is involved in the activation of p53 [85], a
critical tumor suppressor that has been closely tied to redox systems and
oxidative stress [102]. In low oxidative stress conditions, p53 augments
antioxidant protection by upregulating Gpx and other stress resistance
genes to ensure cell survival [102]. In high oxidative stress conditions,
p53 acts as a prooxidant, increasing expression of prooxidative genes,
such as proline oxidase, to initiate a stress cascade that ultimately leads
to cell death [102]. In parallel to its upregulation of prooxidative genes,
p53 inhibits nuclear factor E2-related factor 2 (Nrf2), a critical antiox
idant transcription factor [103], ultimately repressing the expression of
genes involved in glutathione metabolism (namely, GCLM, GCLC, GR,
and cysteine transporter SLC7A11) [104–106]. SLC7A11, also referred
to as xCT, is the regulator of intracellular cysteine, the essential
8
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Fig. 7. High-resolution association mapping of hepatic NADP+ reveals a suggestive QTL on mouse chromosome 3. A. Genome-wide scan of hepatic NADP+ (pmol/
μg) in outbred mice shows a QTL with peak LOD score 7.032 at 110.517 Mbp (48.547 cM) on mouse chromosome 3. Permutation-derived significance thresholds are
indicated by colored lines at significance (α) levels 0.05 (blue), 0.1 (red), and 0.2 (purple). B. The founder allele QTL effects indicate that the NOD and CAST alleles
contribute to a lower hepatic NADP+ concentration, whereas the WSB and PWK alleles contribute to a higher hepatic NADP+ concentration. Each colored line
represents a DO founder allele as indicated in the legend. The differences between strains are considered significant when the LOD score (bottom) crosses significance
thresholds (panel A). C. Candidate genes found within the QTL interval relative to the MGI database. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)

rate-limiting precursor to GSH biosynthesis [86,87,107,108]. Impor
tantly, this full pathway has been validated, confirming that SOCS1
activates p53, driving declines in both SLC7A11 expression and GSH
levels [85]. Our results now suggest that variation in the SOCS1 gene
may have a similar effect.
In addition to its effect on p53 signaling, SOCS1 controls GSH levels
via another prominent transcription factor: NF-κB [84]. NF-kB is
responsive to oxidative stress, and upon activation, it controls expres
sion of GCLC and GCLM, to increase GSH biosynthesis [89,90], and
upregulates other antioxidant and anti-apoptotic proteins [109]. SOCS1
regulates the NF-κB complex by acting as a ubiquitin ligase, specifically
at the p65 subunit, and prompting proteasome-mediated degradation
[88,110–112]. Future research will investigate if promotion of NF-κB
degradation by SOCS1 drives a decline in GSH biosynthesis.
To determine whether SOCS1 has been associated with liver func
tion, we queried databases and published literature. In mice, Socs1
expression was positively associated with hepatic necrosis
(MP:0001654), hepatic steatosis (MP:0002628), liver degeneration

(MP:0003103), and liver inflammation (MP:0001860) [78,113]. Yet
interestingly, Socs1− /− knockout mice are rendered perinatal lethal
[114], and gene deletion resulted in severe liver inflammation [114].
Furthermore, Socs1 methylation in mouse liver is associated with
advancement of liver fibrosis [114]. Therefore, both increases and de
creases in Socs1 expression have been associated with liver dysfunction
in rodents. In humans, a SOCS1 variant (rs243330) was associated with
non-alcoholic fatty liver disease and insulin resistance in obese in
dividuals [115]. Based on these findings, we propose that Socs1 nega
tively regulates hepatic GSH via p53 and NF-kB, ultimately impeding
liver function. Additional studies are needed to validate the specific
effect of Socs1 on GSH/GSSG and better understand its impact on liver
disease.
Next, we mapped phenotypes related to the cofactor NADPH and
discovered suggestive QTL for NADP+ on mouse chromosome 3 at
110.517 Mbp (p≤0.20) and NADP+/NADPH on mouse chromosome 12
at 28.626 Mbp (p≤0.10). Candidate gene analysis for NADP+ and
NADP+/NADPH was inconclusive, with a possible 25 candidate genes
9
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Fig. 8. High-resolution association mapping of hepatic NADP+/NADPH reveals a suggestive QTL on mouse chromosome 12. A. Genome-wide scan of GSH in outbred
mice shows a QTL with peak LOD score 7.637 at 28.626 Mbp (10.987 cM) on mouse chromosome 12. Permutation-derived significance thresholds are indicated by
colored lines at significance (α) levels 0.05 (blue), 0.1 (red), and 0.2 (purple). B. The founder allele QTL effects indicate that the NOD and PWK alleles contribute to a
lower hepatic NADP+/NADPH concentration, whereas the WSB and B6 alleles contribute to a higher hepatic NADP+/NADPH concentration. Each colored line
represents a DO founder allele as indicated in the legend. The differences between strains are considered significant when the LOD score (bottom) crosses significance
thresholds (panel A). C. Candidate genes found within the QTL interval relative to the MGI database. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)

for NADP+ (Clcc1, Gpsm2, Aknad1, Stxbp3, Prpf38b, Henmt1, Fam102b,
Slc25a54, Vav3, Ntng1, Prmt6, Rnpc3, Olfm3, A930005H10Rik, Dph5,
Slc30a7, Extl2, Vcam1, Cdc14a, Rtca, Dbt, Lrrc39, Trmt13, Sass6, and
Slc35a3) and 9 candidate genes for NADP+/NADPH (Sox11, Colec11,
Rps7, Rnaseh1, Adi1, Myt1l, Pxdn, Tpo, and Sntg2). A collection of
functional and phenotypic annotations suggests that Vav3, Vcam1, and
Cdc14a are the most likely genes influencing NADP+ concentrations,
though they have no documented roles in hepatic redox metabolism.
Future studies will be conducted to narrow and eventually select the
causative gene.
Previous genetics research used in silico haplotype association map
ping (HAM) to identify novel loci associated with hepatic and renal GSH
and GSSG concentrations, as well as GSH/GSSG [51]. We compared
those loci to all QTL peaks with LOD scores >6 from the present study
(Supplementary Table S10) to find any loci overlapping between
studies. We did not observe any direct overlap between the previous
HAM results and the current QTL study. Yet we found alignment be
tween our QTL peak for NADP+ on mouse chromosome 8 at 61.237
(60.722–65.378) Mbp and HAM peaks for hepatic GSH on mouse

chromosome 8 at 56.109 Mbp and renal GSSG on mouse chromosome 8
at 54.793 and 55.416 Mbp. Moreover, we documented a QTL peak for
hepatic GSSG on chromosome 1 at 21.043 (18.793–22.050) Mbp which
was near the HAM peak observed for renal GSH on chromosome 1 at
20.259 Mbp. Overall, these results indicate that there could be shared
regulatory mechanisms between the hepatic and renal GSH redox sys
tems, and new research will need to investigate these relationships
further.
Notable in this study was the absence of loci overlapping with ca
nonical genes involved in GSH synthesis and metabolism. We posited
that no such loci were found because DO mice lack significant variation
in those genes. Using R/qtl2, we visualized founder allele effects in the
genetic regions of Gpx1, Gclc, Gclm, Gs, and Gr (Supplementary
Table S11) [113] and concluded that those gene locations contained no
variation that would significantly increase or decrease the phenotype
(Supplementary Figure S5 – S9). Our results support previous conclu
sions that variation in hepatic GSH is not driven by canonical genes
responsible for GSH synthesis and recycling [51], but rather by novel
regulatory loci in mouse models.
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The DO stock is a model of human genetic variation [116] with over
39.8 million documented single nucleotide polymorphisms (SNPs)
available for genome-wide association studies (GWAS), compared to the
human 1000 Genomes Project which had only 8.1 million SNPs avail
able for GWAS [D. Gatti, personal communication, May 5, 2021].
Furthermore, the DO population exhibits traits similar to those of human
disease [69] and may be useful for modeling human variation in phe
notypes that are not readily measurable in patients. For instance, GSH
status [5,117] and circulating GSH/GSSG [118] have been tied to liver
disease severity, yet it is unclear how hepatic GSH varies in the broader
human population. Here, in the DO stock, we observed substantial
variation in GSH phenotypes, with an 11-fold difference in total gluta
thione and GSH concentrations, a 16-fold difference in GSSG concen
trations, and over a 5-fold difference in GSH/GSSG. Moreover, liver
weight, which has been tied to NAFLD [119], exhibited an approxi
mately 5.5-fold variation and correlated with hepatic GSH and GSSG.
Based on our knowledge of this model and its relevance to the human
condition, we predict that human populations may see similar differ
ences in hepatic GSH among individuals, though such a hypothesis must
be carefully addressed in future studies.
It must be noted that the present study was accompanied by some
limitations. Though male and female mice were used in near-equal
numbers, a subset of males (N = 63) had to be individually housed
due to aggressive behavior. Excessive fighting has been associated with
additive stress in mice [120], which had the potential of negatively
influencing GSH due to the molecule’s sensitivity toward external
stressors [52]. To address this issue, we performed Mann-Whitney tests
comparing variables in mice to their housing group size and found that
singly-housed mice did not have significantly different levels of GSH,
NAD(P)H, their redox balances, or liver weights compared to those
housed in greater numbers. Furthermore, to avoid the possibility of
oxidation from prolonged exposure on the HPLC sample plate, all sam
ples were thawed on the sample plate at 4◦ C and analyzed in duplicates
within 4 h of being put on the plate.
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